Sigma Healthcare Ltd

As of June 30, 2026, Sigma Healthcare Limited carries a market capitalization of 26.42B, placing it among publicly traded companies globally. Its enterprise value stands at 27.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Sigma Healthcare Limited's next confirmed earnings release is scheduled for March 4, 2027.

As of June 30, 2026, Sigma Healthcare Limited has 11.50B shares outstanding.

As of June 30, 2026, Sigma Healthcare Limited trades at a trailing price-to-earnings ratio of 53.82. The price-to-sales ratio is 3.52, and the price-to-book ratio stands at 7.64.

As of June 30, 2026, Sigma Healthcare Limited trades at an EV/EBITDA multiple of 40.38 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.70 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 44.16 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 27.72B versus a market cap of 26.42B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Sigma Healthcare Limited maintains a current ratio of 1.67, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 40.50, indicating elevated leverage, while an interest coverage ratio of 21.37 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Sigma Healthcare Limited posted a return on equity (ROE) of 14.67, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.02 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 8.25, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 10.81, useful for judging operating efficiency across full business cycles. Inventory turnover of 7.84 indicates how many times Sigma Healthcare Limited sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Sigma Healthcare Limited recorded 205.13M in income tax expense. That works out to an effective tax rate of 29.49, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 695.55M, leaving 490.78M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Sigma Healthcare Limited's stock has declined approximately 11.62% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Sigma Healthcare Limited generated 7.50B in revenue and converted that into 490.78M in net income, yielding earnings per share of 0.04. EBITDA reached 686.54M, while operating income came in at 627.69M.

As of June 30, 2026, Sigma Healthcare Limited holds 90.74M in cash and equivalents against 1.40B in total debt, resulting in a net debt position of 458.99M. Total book value stands at 3.46B, with working capital of 952.46M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Sigma Healthcare Limited posted a gross margin of 18.06, reflecting its pricing power and cost economics. The operating margin of 8.37 and net profit margin of 6.55 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Sigma Healthcare Limited paid dividends of 0.02 per share. The dividend payout ratio of 53.50 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.69, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Sigma Healthcare Limited shareholders.

Sigma Healthcare Limited's most recent stock split took place on December 13, 2023.

As of June 30, 2026, Sigma Healthcare Limited has an Altman Z-Score of 9.07, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.